The Association Between Liver Histology and Cardiovascular Risk: Time to Introduce Steatotic Liver Disease Screening in High-Risk Patient Groups?

Abstract

Keywords

non-alcoholic fatty liver disease metabolic dysfunction–associated steatotic liver disease cardiovascular risk liver histology

Get full access to this article

View all access options for this article.

References

H-M

Zheng

Chen

, et al. A comparison of the prognostic ability of liver fibrosis scores in AMI patients with and without type 2 diabetes. Angiology 2024;75:219-230.

Boutari

Mantzoros

. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism 2022;133:155217.

Mullish

Forlano

Manousou

Mikhailidis

. Non-alcoholic fatty liver disease and cardiovascular risk: an update. Expert Rev Gastroenterol Hepatol 2018;12:1175-1177.

Rinella

Lazarus

Ratziu

, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-1556.

Kokkorakis

Boutari

Katsiki

Mantzoros

. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism 2023;147:155664.

Mazidi

Katsiki

Mikhailidis

Banach

. Ideal cardiovascular health associated with fatty liver: results from a multi-ethnic survey. Atherosclerosis 2019;284:129-135.

Katsiki

Perez-Martinez

Anagnostis

Mikhailidis

Karagiannis

. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol 2017;16:219-227.

Katsiki

Athyros

Mikhailidis D

. Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: an underestimated predictor of vascular risk? Curr Vasc Pharmacol 2016;14:432-441.

Boutari

Mantzoros

. Inflammation: a key player linking obesity with malignancies. Metabolism 2018;81:A3–A6.

10.

Muzurović

Peng

CCH

Belanger

Sanoudou

Mikhailidis

Mantzoros

. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension 2022;79:1319-1326.

11.

Muzurović

Mikhailidis

Mantzoros

. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021;119:154770.

12.

Mózes

Lee

Selvaraj

, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022;71:1006-1019.

13.

Goyale

Jain

Smith

, et al. Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS One 2021;16:e0260313.

14.

Cusi

Isaacs

Barb

, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28:528-562.

15.

Younossi

Corey

Lim

. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology 2021;160:912-918.

16.

Stahl

Dhindsa

Lee

Sandesara

Chalasani

Sperling

. nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:948-963.

17.

Arnett

Blumenthal

Albert

, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74:e177-232.

18.

Cosentino

Grant

Aboyans

, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323.

19.

Wong

Yeung

, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology 2016;63:754-763.

20.

Baratta

Pastori

Angelico

, et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol 2020;18:2324-2331.

21.

Tamaki

Kurosaki

Takahashi

, et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol 2021;36:2960-2966.

22.

Katsiki

Stoian

Rizzo

. Dietary patterns in non-alcoholic fatty liver disease (NAFLD): stay on the straight and narrow path. Clínica e Investig en Arterioscler 2022;34:S24-31.

23.

Wahid

Manek

Nichols

, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and Meta-Analysis. J Am Heart Assoc 2016;5:e002495.

24.

Eslam

Sarin

Wong

, et al. The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14:889-919.

25.

Vilar-Gomez

Martinez-Perez

Calzadilla-Bertot

, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367-378.

26.

Tang

Desai

Hamilton

, et al. Accuracy of MR imaging–estimated proton density fat fraction for classification of dichotomized histologic Steatosis grades in nonalcoholic fatty liver disease. Radiology 2015;274:416-425.

27.

Sattar

McGuire

Pavo

, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 2022;28:591-598.

28.

Mantovani

Petracca

Csermely

Beatrice

Targher

. Sodium-Glucose Cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites 2021;11:1-11.

29.

Rinella

Neuschwander-Tetri

Siddiqui

, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023;77:1797-1835.

30.

Belfort

Harrison

Brown

, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic Steatohepatitis. N Engl J Med 2006;355:2297-2307.

31.

Athyros

Alexandrides

Bilianou

, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017;71:17-32.

32.

Athyros

Tziomalos

Gossios

, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-1922.